Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
about
Nucleostemin mRNA is expressed in both normal and malignant renal tissuesA generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma.Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinomaIntegrative genome-wide gene expression profiling of clear cell renal cell carcinoma in Czech Republic and in the United StatesChemokines as therapeutic targets in renal cell carcinomaCXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer.Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies.A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus.Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts.Combination of physical activity, nutrition, or other metabolic factors and vaccine responseCombined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring a PIK3CA Mutation.Life-threatening gastrointestinal bleeding during targeted therapy for advanced renal cell carcinoma: a case report.Signaling pathways in renal cell carcinoma.EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcomeSystemic adjuvant therapies in renal cell carcinomaKidney cancer is characterized by aberrant methylation of tissue-specific enhancers that are prognostic for overall survival.Sunitinib re-challenge in advanced renal-cell carcinoma.Microvessel density and heparanase over-expression in clear cell renal cell cancer: correlations and prognostic significancesMolecular classification of renal tumors by gene expression profiling.Challenges and perspective of drug repurposing strategies in early phase clinical trials.VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.A cell-penetrating peptide suppresses the hypoxia inducible factor-1 function by binding to the helix-loop-helix domain of the aryl hydrocarbon receptor nuclear translocatorExpression of carbonic anhydrase 9, a potential intrinsic marker of hypoxia, is associated with poor prognosis in oesophageal squamous cell carcinoma.Angiogenesis genotyping in the selection of first-line treatment with either sunitinib or pazopanib for advanced renal cell carcinoma.Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma.Multiphasic contrast-enhanced MRI: single-slice versus volumetric quantification of tumor enhancement for the assessment of renal clear-cell carcinoma fuhrman grade.Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer[Advances in the research of glycolysis and lung cancer].
P2860
Q24651568-012916DD-409E-47BA-BC56-4FFB63988268Q24814644-086BC0D8-C943-4C20-A0B2-000C40DD6A5EQ27851432-DE5E8A57-A2A2-4362-A819-CB2E05C72342Q28487676-A9BA624D-CC70-42FC-9FEE-A87C2E1CBB3DQ30435873-0963B378-6DCB-429A-865C-901886557457Q30439235-0CB5B8DB-5109-4B04-91BD-5EF615AFF334Q30447049-D28444E1-1793-454C-8ECD-9D9BAEFA0ADEQ33397006-49BD26EF-3719-4AAC-854B-8C8FFDC3F1AFQ33414370-0CC88846-58D6-4390-B2C8-12CD7BAB9C5CQ33423777-05E3DDA4-D3A6-4F70-BFC6-7B9BC482945BQ33594289-58BF61F0-E3AB-4067-83AB-EE0DFEA808B0Q33751144-7073EFD4-5BCD-49C5-9C1C-66B710F590D4Q34340644-A027B964-A399-446C-8CA2-80892227B9D7Q34809995-32929635-0DC4-4A07-8EDE-994CC3643EC0Q34978827-3639F0C4-4809-452B-A8BA-5BEB1AC1E9A3Q35000659-9335F44E-FC50-4BD2-BFC3-6DD36DEE6352Q35569322-C296E6CA-DFA0-454B-8DD3-DAF49397A945Q35582141-86310406-05E4-4FC7-8DCA-E747E1718587Q35678358-85F884B0-7994-41EF-8E8E-35B4BB5538B0Q35707564-E9E5F7C2-73C5-46CE-B3F3-F1CFCD525647Q35789932-EFC7D2A1-0E6B-4B48-90EC-E041F5BEF79AQ35863063-D4460ED5-7663-4000-B256-7D37894F4A6FQ36746698-390F14E2-C864-465C-B11E-64F59871CD0CQ36865718-07745D88-1036-433C-B2F4-70840553B582Q36965105-270CF49E-359E-4F14-8CBC-EC1B625A0602Q37437235-F0413505-FB56-4630-915E-75F1FE5534F0Q37461792-95A16BA9-0D96-4F78-A265-26607F08CADAQ37708077-3DB21EE2-173D-40EE-A6E5-FBF91271D0EBQ39960762-3692735D-4AC5-491E-B52C-D088B86685CAQ55464273-65765888-98E1-4D19-82B8-A5CA5BEC3C92
P2860
Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Pathobiology, prognosis, and t ...... g the hypoxia-induced pathway.
@ast
Pathobiology, prognosis, and t ...... g the hypoxia-induced pathway.
@en
type
label
Pathobiology, prognosis, and t ...... g the hypoxia-induced pathway.
@ast
Pathobiology, prognosis, and t ...... g the hypoxia-induced pathway.
@en
prefLabel
Pathobiology, prognosis, and t ...... g the hypoxia-induced pathway.
@ast
Pathobiology, prognosis, and t ...... g the hypoxia-induced pathway.
@en
P2093
P1476
Pathobiology, prognosis, and t ...... ng the hypoxia-induced pathway
@en
P2093
Allan J Pantuck
Arie S Belldegrun
Robert A Figlin
P304
P407
P577
2003-10-01T00:00:00Z